Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
ROIV
ROIV
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
Latest ROIV ETF News Today | Earnings, Events & Price Alerts
ROIV News
Priovant Secures FDA Priority Review for Brepocitinib
8h ago
seekingalpha
Priovant's Dermatomyositis Drug Receives FDA Priority Review
8h ago
Newsfilter
Perceptive Advisors Increases Stake in Celcuity
Feb 22 2026
Yahoo Finance
Roivant Sciences (ROIV.US) Officer Plans to Sell $44.03 Million in Common Stock via Form 144
Feb 20 2026
moomoo
David Einhorn's Concerns on AI Overvaluation Impacting Stock Picks
Feb 18 2026
CNBC
Citi and H.C. Wainwright Raise Roivant Sciences Price Targets Following Positive Drug Data
Feb 14 2026
Yahoo Finance
Roivant Sciences (ROIV.US) Officer Plans to Sell $5.3 Million in Common Stock via Form 144
Feb 13 2026
moomoo
Top Performing Large-Cap Stocks Last Week
Feb 08 2026
Benzinga
Roivant Sciences Q3 2025 Earnings Call Highlights
Feb 06 2026
seekingalpha
U.S. Markets Increased on Friday; Strategy Reached New Heights
Feb 06 2026
Barron's
Roivant Sciences Stock Soars on Positive Phase 2 Results for Brepocitinib
Feb 06 2026
Benzinga
Molina Healthcare Stock Plummets 29% After Earnings Miss
Feb 06 2026
Benzinga
U.S. Stocks Rise, AutoNation Shares Surge
Feb 06 2026
Benzinga
U.S. Stocks Rise as Dow Jones Gains Over 700 Points
Feb 06 2026
Benzinga
Priovant Reports Positive Mid-Stage Trial Results for Brepocitinib in Cutaneous Sarcoidosis
Feb 06 2026
seekingalpha
Roivant Sciences Reports Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis
Feb 06 2026
stocktwits
Show More News
